Business Weekly newspaper

SeqOne in France buying Sanger spin-out Congenica to create world leader in AI-powered genomic medicine Cambridge-based Congenica is being acquired for an undisclosed sum by French company SeqOne but the new entity will retain a base at the Wellcome Sanger Institute from where it was spun out.

Cambridge-based Congenica is being acquired for an undisclosed sum by French company SeqOne but the new entity will retain a base at the Wellcome Sanger Institute from where it was spun out. Full article – www.businessweekly.co.uk/posts/seqone...

Decades of DNA sequencing data from UK child development study released The first resource containing high-resolution DNA sequencing data for over 37,000 children and parents collected over multiple decades from across the UK is now available to researchers worldwide. The...

The first resource containing high-resolution DNA sequencing data for over 37,000 children and parents collected over multiple decades from across the UK is now available to researchers worldwide.

@sangerinstitute.bsky.social

Full article – www.businessweekly.co.uk/posts/decade...

Cambridge Innovation Capital to curate Start Codon future For DeepTech funder Cambridge Innovation Capital, it’s a case of back to the future after its decision to take venture builder Start Codon under its management. CIC Partner Michael Anstey, who special...

For DeepTech funder Cambridge Innovation Capital, it’s a case of back to the future after its decision to take venture builder Start Codon under its management.

www.businessweekly.co.uk/posts/cambri...

Sortera Bio spins out of MRC LMB with revolutionary tech Sortera Bio Ltd has spun out of the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to pioneer a Deep Screening platform set to redefine early biologics discovery and engineering. I...

Sortera Bio Ltd has spun out of the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to pioneer a Deep Screening platform set to redefine early biologics discovery and engineering.

www.businessweekly.co.uk/posts/sorter...

ExpressionEdits and Boehringer Ingelheim collaborate to enhance gene therapies ExpressionEdits in Cambridge has clinched unspecified riches from global pharmaceutical company Boehringer Ingelheim through a collaboration and licensing agreement.

ExpressionEdits in Cambridge has clinched unspecified riches from Boehringer Ingelheim through a collaboration and licensing agreement. Boehringer will leverage ExpressionEdits’ Genetic Syntax Engine for two gene therapy targets.

www.businessweekly.co.uk/posts/expres...

Cambridge Consultants brainpower sparks protein engineering AI revolution Cambridge Consultants, which is a DeepTech powerhouse subsidiary of French company Capgemini SE, is the brains behind a cutting edge advancement in generative AI.

Cambridge Consultants, a subsidiary of Capgemini SE, is the brains behind a new generative AI-driven methodology for protein engineering that uses a specialised protein large language model (pLLM) to predict the most effective protein variants.

www.businessweekly.co.uk/posts/cambri...

ClariMed opens research facility in Cambridge US MedTech company ClariMed Inc. has unveiled a new study facility in Cambridge to advance human factors research capabilities.

US MedTech company ClariMed Inc. has opend a study facility in Cambridge UK to advance human factors #research capabilities, expanding its capacity to host and conduct research to support user-centered medical device development.

Full article – www.businessweekly.co.uk/posts/clarim...

Qureight and Avalyn join forces to combat pulmonary fibrosis A transatlantic Cambridge2Cambridge alliance between Qureight in the UK and Avalyn Pharma Inc in Massachusetts – is seeking to improve treatment of pulmonary fibrosis (PPF) for which there is currentl...

Qureight and Avalyn Pharma join forces to combat pulmonary fibrosis

www.businessweekly.co.uk/posts/qureig...

Are we thinking we are back? Since the heady highs of investment during the Covid years, it has been extremely challenging in terms of the funding environment for the region’s life science companies, impacting all stakeholders – ...

Are we thinking we are back? – Guest article by Tony Jones, CEO of One Nucleus

www.businessweekly.co.uk/posts/are-we...

New screening device shows promise for early lung cancer detection Cranfield University scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even bef...

New screening device shows promise for early lung cancer detection

www.businessweekly.co.uk/posts/new-sc...

Solid gold future as Astex pursues further growth in wake of silver jubilee Cambridge biotech company Astex belatedly celebrated its 25th anniversary in style with UK Science Minister and new trade tsar Lord Vallance leading the salutes at the company’s Science Park HQ.

Solid gold future as Astex pursues further growth in wake of silver jubilee

www.businessweekly.co.uk/posts/solid-...

VasoDynamics: Born of sadness but designed to generate many happy outcomes Fiona Li learned early how cancer could end a life and devastate others within a circle of family or friends. She and a friend were inseparable. They would walk to and from school hand in hand, smilin...

VasoDynamics: Born of sadness but designed to generate many happy outcomes

www.businessweekly.co.uk/posts/vasody...

Nasdaq shares climb as Arm posts record Q3 results and soaring chip demand Cambridge UK superchip architect Arm saw its stock on the Nasdaq market in the US climb almost seven per cent and $11 to $173.26 after posting record Q3 revenues. Its market cap hit $182.10 billion.

Nasdaq shares climb as Arm posts record Q3 results and soaring chip demand

www.businessweekly.co.uk/posts/nasdaq...

Paragraf and University of Cambridge in graphene tech advance Paragraf, which is pioneering the mass production of graphene-based electronics with standard semiconductor processes, has been awarded a grant of c£420k from Innovate UK to produce a proof-of-concept...

Paragraf and University of Cambridge in graphene tech advance

www.businessweekly.co.uk/posts/paragr...

AstraZeneca leads FTSE charge with shares surge and higher dividend Some market watchers had a quiet chuckle when Cambridge-based pharmaceutical giant AstraZeneca said it was targeting $80 billion total revenue by the end of the decade. They’re not laughing now!

AstraZeneca leads FTSE charge with shares surge and higher dividend

www.businessweekly.co.uk/posts/astraz...